Advertising

Eli Lilly & Co.

LLY-N

NYSE:LLY

230.10
0.94 (0.41%)
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
More at Wikipedia

Analysis and Opinions about LLY-N

Signal
Opinion
Expert
Chart
BUY
BUY
August 18, 2021
Trades at 34x PE, because investors believe in LLY's new Alzheimer's drug. Also, all drug stocks are rallying because of the Delta variant and calls for a booster shot.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
August 18, 2021
Trades at 34x PE, because investors believe in LLY's new Alzheimer's drug. Also, all drug stocks are rallying because of the Delta variant and calls for a booster shot.
Jim Cramer - Mad Money
Price
$268.520
Owned
Unknown
COMMENT
COMMENT
June 7, 2021
Eli bounced today off Biogen's monster move after the FDA greenlit the latter's Alzheimer's drug.
Show full opinionHide full opinion
Eli bounced today off Biogen's monster move after the FDA greenlit the latter's Alzheimer's drug.
Jim Cramer - Mad Money
Price
$222.520
Owned
Unknown
BUY
BUY
February 22, 2021
A fave of his, up 19% YTD. Last month they delivered a terrific quarter and strong phase 2 data on their Alzheimer's drug, a possible game-changer. They also have a Covid antibody treatment that's already selling well. Most recentlty they delivered good phase 3 trial results on their cholesterol, weighr-loss drug for diabetes.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
February 22, 2021
A fave of his, up 19% YTD. Last month they delivered a terrific quarter and strong phase 2 data on their Alzheimer's drug, a possible game-changer. They also have a Covid antibody treatment that's already selling well. Most recentlty they delivered good phase 3 trial results on their cholesterol, weighr-loss drug for diabetes.
Jim Cramer - Mad Money
Price
$200.680
Owned
Unknown
RISKY BUY
RISKY BUY
February 16, 2021
Allan Tong’s Discover Picks LLY stock is now flirting with 52-week highs and trading above its 50- and 200-day moving averages. It trades at 25.55x and pays a 1.64% dividend. Essentially, positive news on March 12 will launch the LLY stock—and alleviate the suffering of many people and their families—but negative headlines will sink it, which might make it an even bigger bargain stock. Read 3 Bargain Stocks: Eli Lilly, Unilever & Apple for our full analysis.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
February 16, 2021
Allan Tong’s Discover Picks LLY stock is now flirting with 52-week highs and trading above its 50- and 200-day moving averages. It trades at 25.55x and pays a 1.64% dividend. Essentially, positive news on March 12 will launch the LLY stock—and alleviate the suffering of many people and their families—but negative headlines will sink it, which might make it an even bigger bargain stock. Read 3 Bargain Stocks: Eli Lilly, Unilever & Apple for our full analysis.
BUY
BUY
February 11, 2021
Recent great results on phase 2 of Alzheimer's testing. There will be a lot of focus on the results around March 12. It it works, tremendous upside. Huge for families and for LLY. Diabetes franchise is performing extremely well. Oncology is building out.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
February 11, 2021
Recent great results on phase 2 of Alzheimer's testing. There will be a lot of focus on the results around March 12. It it works, tremendous upside. Huge for families and for LLY. Diabetes franchise is performing extremely well. Oncology is building out.
Paul MacDonald
Price
$202.120
Owned
Unknown
COMMENT
COMMENT
January 22, 2021
Their stock has rallied so much after vaccine hopes that it's now cooling off. Their pipeline of drugs is super. Any further positive news about their Alzheimer's drug push this stock higher.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
January 22, 2021
Their stock has rallied so much after vaccine hopes that it's now cooling off. Their pipeline of drugs is super. Any further positive news about their Alzheimer's drug push this stock higher.
Jim Cramer - Mad Money
Price
$206.140
Owned
Unknown
BUY
BUY
October 19, 2020
He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
October 19, 2020
He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.
Robert Lauzon
Price
$143.860
Owned
Yes
BUY
BUY
September 21, 2020
They just released very promising data on their breast cancer drug (the previous update in June saw the stock pop), but the stock still dropped in price today. This is strange and undeserved, but the selling won't last.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
September 21, 2020
They just released very promising data on their breast cancer drug (the previous update in June saw the stock pop), but the stock still dropped in price today. This is strange and undeserved, but the selling won't last.
Jim Cramer - Mad Money
Price
$151.180
Owned
Unknown
DON'T BUY
DON'T BUY
August 2, 2019
He sold it several months ago, because it outperformed like crazy in late-2018. That was expected, because healthcare is the most defensive sector and Q4 was a bear market with fears of a recession. LLY made an acquisition in oncology and one of their big drugs got withdrawn. Novo Nordisk may launch a diabetes drug in September to fcompete with LLY.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
August 2, 2019
He sold it several months ago, because it outperformed like crazy in late-2018. That was expected, because healthcare is the most defensive sector and Q4 was a bear market with fears of a recession. LLY made an acquisition in oncology and one of their big drugs got withdrawn. Novo Nordisk may launch a diabetes drug in September to fcompete with LLY.
David Fingold
Price
$111.600
Owned
No
TOP PICK
TOP PICK
July 8, 2019
It has one of the best growth profiles on the street with EPS growth at 10%. It trades at a premium to its peers, though. They have some potential blockbuster drugs focused on diabetes and heart disease. Itt depends on the effectiveness of that drug. Now is a good entry point. (Analysts’ price target is $125.81)
Show full opinionHide full opinion
It has one of the best growth profiles on the street with EPS growth at 10%. It trades at a premium to its peers, though. They have some potential blockbuster drugs focused on diabetes and heart disease. Itt depends on the effectiveness of that drug. Now is a good entry point. (Analysts’ price target is $125.81)
Jamie Murray
Price
$111.520
Owned
Yes
DON'T BUY
DON'T BUY
May 30, 2019
The whole drug industry is a slow growth one. It is difficult to get top line growth. That growth tends to come from a revolving set of assets. MRK-N has a bit of a leg up and is growing rapidly. It has a long runway before patent expiration. He prefers MRK-N.
Show full opinionHide full opinion
The whole drug industry is a slow growth one. It is difficult to get top line growth. That growth tends to come from a revolving set of assets. MRK-N has a bit of a leg up and is growing rapidly. It has a long runway before patent expiration. He prefers MRK-N.
Gordon Reid
Price
$115.900
Owned
Unknown
WATCH
WATCH
May 3, 2019
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
Show full opinionHide full opinion
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
Paul MacDonald
Price
$116.970
Owned
Yes
PAST TOP PICK
PAST TOP PICK
April 15, 2019
(A Top Pick Dec 18/18, Up 17%) He owned a lot in this sector and sold on strength. He would have no problem buying it if he did not have a healthcare stock. It is one of the few areas that are truly in a secular bull market.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
April 15, 2019
(A Top Pick Dec 18/18, Up 17%) He owned a lot in this sector and sold on strength. He would have no problem buying it if he did not have a healthcare stock. It is one of the few areas that are truly in a secular bull market.
HOLD
HOLD
April 8, 2019
He is not yet taking profits. They dominate the insulin business. As the world gets larger and overeats … The stock takes patience. It will probably sell off with the market.
Show full opinionHide full opinion
He is not yet taking profits. They dominate the insulin business. As the world gets larger and overeats … The stock takes patience. It will probably sell off with the market.
Bruce Murray
Price
$127.130
Owned
Yes
WATCH
WATCH
March 22, 2019
What does the increase in volume signal? Some technicians see volume as confirmation. You need volume spike to confirm a move. On the downside, volume doesn't tell you a lot, as things can start slowly. So don't read too much into it. If this stock comes back down to north of $105, a lot of investors would probably come back in. A good name, if you didn't want to buy XLD or HHL.T.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
March 22, 2019
What does the increase in volume signal? Some technicians see volume as confirmation. You need volume spike to confirm a move. On the downside, volume doesn't tell you a lot, as things can start slowly. So don't read too much into it. If this stock comes back down to north of $105, a lot of investors would probably come back in. A good name, if you didn't want to buy XLD or HHL.T.
Showing 1 to 15 of 49 entries

Eli Lilly & Co.(LLY-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Eli Lilly & Co. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Eli Lilly & Co.(LLY-N) Frequently Asked Questions

What is Eli Lilly & Co. stock symbol?

Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N

Is Eli Lilly & Co. a buy or a sell?

In the last year, 6 stock analysts published opinions about LLY-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Eli Lilly & Co..

Is Eli Lilly & Co. a good investment or a top pick?

Eli Lilly & Co. was recommended as a Top Pick by Jim Cramer - Mad Money on 2021-08-18. Read the latest stock experts ratings for Eli Lilly & Co..

Why is Eli Lilly & Co. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Eli Lilly & Co. worth watching?

6 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.

What is Eli Lilly & Co. stock price?

On 2021-09-17, Eli Lilly & Co. (LLY-N) stock closed at a price of $230.1.